Sedona Sweeney1, Zoe Ward2, Lucy Platt1, Lorna Guinness1, Matthew Hickman2, Vivian Hope3, Lisa Maher4, Jenny Iversen4, Sharon J Hutchinson5, Josie Smith6, Rachel Ayres7, Ingrid Hainey8, Peter Vickerman2. 1. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. 2. Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK. 3. Public Health Institute, Liverpool John Moores University, Liverpool, UK. 4. Kirby Institute for Infection and Immunity, UNSW, Sydney, Australia. 5. Glasgow Caledonian University, Glasgow, Scotland, UK. 6. Public Health Wales, Cardiff, Wales, UK, CF10 4BZ. 7. Bristol Drugs Project, Bristol, UK. 8. Cair Scotland, Dundee, Scotland, UK.
Abstract
AIM: To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared with no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. DESIGN: Cost-effectiveness analysis from a National Health Service (NHS)/health-provider perspective, utilizing a dynamic transmission model of HCV infection and disease progression, calibrated using city-specific surveillance and survey data, and primary data collection on NSP costs. The effectiveness of NSPs preventing HCV acquisition was based on empirical evidence. SETTING AND PARTICIPANTS: UK settings with different chronic HCV prevalence among people who inject drugs (PWID): Dundee (26%), Walsall (18%) and Bristol (45%) INTERVENTIONS: Current NSP provision is compared with a counterfactual scenario where NSPs are removed for 10 years and then returned to existing levels with effects collected for 40 years. MEASUREMENTS: HCV infections and cost per quality-adjusted life year (QALY) gained through NSPs over 50 years. FINDINGS: Compared with a willingness-to-pay threshold of £20 000 per QALY gained, NSPs were highly cost-effective over a time-horizon of 50 years and decreased the number of HCV incident infections. The mean incremental cost-effectiveness ratio was cost-saving in Dundee and Bristol, and £596 per QALY gained in Walsall, with 78, 46 and 40% of simulations being cost-saving in each city, respectively, with differences driven by coverage of NSP and HCV prevalence (lowest in Walsall). More than 90% of simulations were cost-effective at the willingness-to-pay threshold. Results were robust to sensitivity analyses, including varying the time-horizon, HCV treatment cost and numbers of HCV treatments per year. CONCLUSIONS: Needle and syringe programmes are a highly effective low-cost intervention to reduce hepatitis C virus transmission, and in some settings they are cost-saving. Needle and syringe programmes are likely to remain cost-effective irrespective of changes in hepatitis C virus treatment cost and scale-up.
AIM: To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared with no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. DESIGN: Cost-effectiveness analysis from a National Health Service (NHS)/health-provider perspective, utilizing a dynamic transmission model of HCV infection and disease progression, calibrated using city-specific surveillance and survey data, and primary data collection on NSP costs. The effectiveness of NSPs preventing HCV acquisition was based on empirical evidence. SETTING AND PARTICIPANTS: UK settings with different chronic HCV prevalence among people who inject drugs (PWID): Dundee (26%), Walsall (18%) and Bristol (45%) INTERVENTIONS: Current NSP provision is compared with a counterfactual scenario where NSPs are removed for 10 years and then returned to existing levels with effects collected for 40 years. MEASUREMENTS: HCV infections and cost per quality-adjusted life year (QALY) gained through NSPs over 50 years. FINDINGS: Compared with a willingness-to-pay threshold of £20 000 per QALY gained, NSPs were highly cost-effective over a time-horizon of 50 years and decreased the number of HCV incident infections. The mean incremental cost-effectiveness ratio was cost-saving in Dundee and Bristol, and £596 per QALY gained in Walsall, with 78, 46 and 40% of simulations being cost-saving in each city, respectively, with differences driven by coverage of NSP and HCV prevalence (lowest in Walsall). More than 90% of simulations were cost-effective at the willingness-to-pay threshold. Results were robust to sensitivity analyses, including varying the time-horizon, HCV treatment cost and numbers of HCV treatments per year. CONCLUSIONS: Needle and syringe programmes are a highly effective low-cost intervention to reduce hepatitis C virus transmission, and in some settings they are cost-saving. Needle and syringe programmes are likely to remain cost-effective irrespective of changes in hepatitis C virus treatment cost and scale-up.
Authors: Magdalena Cerdá; Mohammad S Jalali; Ava D Hamilton; Catherine DiGennaro; Ayaz Hyder; Julian Santaella-Tenorio; Navdep Kaur; Christina Wang; Katherine M Keyes Journal: Epidemiol Rev Date: 2022-01-14 Impact factor: 6.222
Authors: Louis Macgregor; Zoe Ward; Natasha K Martin; Jane Nicholls; Monica Desai; Ford Hickson; Peter Weatherburn; Matthew Hickman; Peter Vickerman Journal: J Viral Hepat Date: 2021-04-01 Impact factor: 3.517
Authors: Jesse L Goldshear; Kelsey A Simpson; Alex H Kral; Lynn D Wenger; Ricky N Bluthenthal Journal: Subst Use Misuse Date: 2021-03-26 Impact factor: 2.362
Authors: Juan M Pericàs; Daniel J Bromberg; Denise Ocampo; Eberhard Schatz; Iwona Wawer; Piotr Wysocki; Kelly Safreed-Harmon; Jeffrey V Lazarus Journal: Harm Reduct J Date: 2019-03-21
Authors: Adam Trickey; Nadiya Semchuk; Tetiana Saliuk; Yana Sazonova; Olga Varetska; Josephine G Walker; Aaron G Lim; Jack Stone; Peter Vickerman Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396